An observation study of pancreatic endocrine secretion after glucagon infusion on the patients that were operated with a subtotal pancreatectomy

Not Applicable

• Conditions: Pancreatic biliary tract disease including malignant disorders is planned a subtotal pancreatectomy

• Registration Number: JPRN-UMIN000004644
• Lead Sponsor: Hiroshima University Hospital Department of Endocrinology and Diabetes mellitus

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2010-12-02
• Study Completion: 2019-07-09
• Last Update Posted: 17 October 2023

Recruitment & Eligibility

• Status: Complete: follow-up complete
• Sex: All
• Target Recruitment: 100

Inclusion Criteria

Not provided

Exclusion Criteria

(a) Patients with a history of total pancreatectomy. (b) Patients with insulin-dependent diabetes mellitus.(Fatigue serum C-peptide under 0.5 ng/ml or 24hr C-peptide under 20 microg/day) (c) Patients with a history of severe cardiovascular or cerebrovascular disease or renal failure. (d) Patients have contraindication of glucagon. (e) Patients with severe liver damage. (f) Patients are pregnant or patients breast-feeding, potentially pregnant. (g) Patients who are diagnosed to be ineligible by the investigator.

Study & Design

• Study Type: Observational
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Delta C-peptide in glucagon injection. (delta C-peptide = max C-peptide - base C-peptide) Observation of the mean of delta C-peptide from before to the end of study.